News

The phase I study is designed to investigate the safety and tolerability of a single dose of the drug in healthy volunteers. As a next step in the

The study, conducted by Dr Qi Dai, assistant professor of Medicine at Vanderbilt University Medical Center, and colleagues, appears in the September issue of The American Journal of

The drug was shown to decrease a number of inflammatory proteins. Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling

AnorMed's lead product, Mozibil, is currently in a phase III trial in multiple myeloma, and a second phase III trial in non-Hodgkin's lymphoma. Dr Joe Dougherty, chairman of

The study will focus on “vulnerable” plaque, a lipid-rich coronary plaque that suddenly ruptures, believed to be the cause of most heart attacks. The study enrolled 700 acute

The collaboration expands on a previously announced project in which the companies sought to validate the use of Immunetrics in silico models of inflammation in predicting the outcomes

The decision, following a portfolio review at Roche, has no effect on the companies’ ongoing collaboration to co-develop daclizumab in transplant maintenance, and the companies intend to proceed

Enrollment in both trials has significantly outpaced the company’s expectations. As a result its clinical research organizations are still in the process of allocating the resources required to

In the preclinical studies, the active compound was able to inhibit the varicella zoster virus (the root cause of shingles) much more quickly than acyclovir, which is marketed